This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
13 Dec 2016

Perrigo to restructure its Branded Consumer Healthcare business

Actions will help to improve the company's financial profile.

Perrigo Company has announced its intention to restructure the Branded Consumer Healthcare's (BCH) Omega Pharma Belgium business (which includes Omega Pharma Belgium NV, Etixx NV and Biover NV), located in Nazareth, Venecoweg 26 (Belgium) to improve the financial profile and enhance focus of the business on branded consumer OTC products.

Perrigo's CEO John Hendrickson stated: "Consistent with our previously announced comprehensive portfolio review, we are [...] announcing specific actions to streamline operations and safeguard the future of our BCH Belgium business. The action plan for Belgium is directed at enhancing long-term profitability by focusing our efforts on growing our OTC brand portfolio. Today's announcement furthers the Perrigo Board of Directors' and management's commitment to delivering shareholder value."

To improve the financial profile of the BCH Belgium business, the company:

  • Signed a definitive agreement with EuroGenerics to terminate their existing distribution agreement to distribute product for STADA Arzneimittel in Belgium effective 31 December 2016
  • Signed a definitive agreement to sell the Etixx brand and its business effective 1 January 2017
  • Allowed for the natural expiration of a distribution agreement with MEDA effective December 2016
  • Initiated the consultation process in Belgium to better align the organization to current business and market dynamics.
  • These combined businesses and products are forecasted to achieve calendar year 2016 net sales of approximately $155 million dollars with no contribution to margin.

    The employees of Omega Pharma Belgium NV, Etixx NV and Biover NV have been informed in detail of the business analysis and the intention to restructure the business operations. Today's announcement marks the beginning of a consultation period with employees, as required by Belgian legislation, regarding the intention to restructure the Omega Pharma Belgian operational business unit. This restructuring plan is only related to Omega Pharma Belgium NV, Etixx NV and Biover NV and only activities related to Omega Pharma Belgium are involved in this plan.

    Related News